Current stock page

Catalysts

SRPT Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Sep 4, 2026

SRPT

Catalysts
Sarepta Therapeutics, Inc.
Healthcare· Biotechnology
AIQ Score
NeutralAIQ Edge 8/10
Relative Leader / Watch
Strong Relative Position
Score data as of Sep 4, 2026
Last price
$22.50
-$0.49 (-2.13%)
Latest market quote
Momentum79
Value64
Quality46
Risk Resilience38
Sentiment
View financial data

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Nov 4, 2026

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 58/100

Momentum 79/100 and sentiment before the next covered event.

Recent coverage
5 articles

Updated Sep 6, 2026 · Sentiment 21.07%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 79/100AIQ Edge 8/10 Strong Relative Position
Beat rate
50%
4 of 8 reported periods
Average surprise
+12.3%
Across covered historical reports
Latest result
-123.0%
Aug 5, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Aug 5, 2026$0.22-$0.05-123.0%$366.39M$401.25M
May 6, 2026$0.98$3.16+223.8%$474.16M$730.8M
Feb 25, 2026-$1.03-$3.58-247.6%$369.6M$442.93M
Nov 3, 2025-$0.73-$1.80-147.6%$335.76M$399.36M
Aug 6, 2025$0.83$2.02+142.8%$530.66M$611.09M
May 6, 2025-$0.87-$4.60-428.7%$687.47M$744.86M
Feb 26, 2025$1.38$1.50+8.7%$631.03M$658.41M
Nov 6, 2024-$0.06$0.34+670.2%$407.17M$467.17M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Hold
8
Buy
11
Hold
5
Sell
12-month analyst target
$24.43
+8.58% versus current price
Based on 7 analyst observations. Targets are estimates, not predictions.
Low target
$14.00
-37.78% vs latest price
Average target
$24.43
+8.58% vs latest price
High target
$35.00
+55.56% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateNov 4, 2026

Next known earnings or reporting date.

EPS estimate$0.17

Current analyst expectation for the upcoming report.

Revenue estimate$354.38M

Current analyst expectation for the upcoming report.

Sentiment score

News pressure around the setup.

Momentum score79

Where event reaction would show up first.

AIQ score58/100

Composite decision read before event confirmation.

Analyst context

Consensus
Hold
Analysts
7
Average target
$24.43
Target upside
8.58%
Target range
$14.00 - $35.00
90-day revisions
-58

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
2
Neutral
3
Negative
0
seekingalpha.com · Aug 28, 2026

Sarepta Stock: A Prove-It Story Now Defined By ELEVIDYS Execution (NASDAQ:SRPT)

Sarepta (SRPT) is rated hold: ELEVIDYS uptake faces friction and execution risk despite better profitability. Read here for a detailed investment analysis.

seekingalpha.com · Aug 6, 2026

Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript

Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsTamara Thornton - Director of Finance, Treasury &...

seekingalpha.com · Aug 6, 2026

Sarepta Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:SRPT) 2026-08-06

2026-08-06. The following slide deck was published by Sarepta Therapeutics, Inc.

finance.yahoo.com · Aug 6, 2026

Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary

Moby summary of Sarepta Therapeutics, Inc.'s Q2 2026 earnings call

seekingalpha.com · Jun 18, 2026

Sarepta: Caution Still Warranted Despite FDA's Gene Therapy Friendly Stance (NASDAQ:SRPT)

Sarepta Therapeutics faces a challenging outlook, with 2025 marked by safety setbacks, missed endpoints, and a sharp price decline. See why SRPT stock is a hold.

Open full news and sentiment

SRPT Catalysts FAQ

What are the next catalysts for SRPT stock?

SRPT's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move SRPT stock?

Upcoming events that could move SRPT include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could SRPT's next earnings report affect the stock?

SRPT's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive SRPT stock higher?

SRPT could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt SRPT stock?

SRPT could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.